APLS
Price
$27.95
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
18 days until earnings call
RCUS
Price
$17.86
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
19 days until earnings call
Ad is loading...

APLS vs RCUS

Header iconAPLS vs RCUS Comparison
Open Charts APLS vs RCUSBanner chart's image
Apellis Pharmaceuticals
Price$27.95
Change-$0.00 (-0.00%)
Volume$1.19M
CapitalizationN/A
Arcus Biosciences
Price$17.86
Change-$0.00 (-0.00%)
Volume$897.38K
CapitalizationN/A
View a ticker or compare two or three
APLS vs RCUS Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
APLS vs. RCUS commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a StrongSell and RCUS is a StrongBuy.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (APLS: $27.95 vs. RCUS: $17.86)
Brand notoriety: APLS and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 60% vs. RCUS: 146%
Market capitalization -- APLS: $3.51B vs. RCUS: $1.41B
APLS [@Biotechnology] is valued at $3.51B. RCUS’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, RCUS is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 6 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 5 bearish.
  • RCUS’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а +3.90% price change this week, while RCUS (@Biotechnology) price change was +0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2025.

RCUS is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($3.51B) has a higher market cap than RCUS($1.41B). RCUS YTD gains are higher at: -6.492 vs. APLS (-53.308). RCUS has higher annual earnings (EBITDA): -235M vs. APLS (-298.3M). RCUS has more cash in the bank: 969M vs. APLS (360M). RCUS has less debt than APLS: RCUS (11M) vs APLS (475M). APLS has higher revenues than RCUS: APLS (629M) vs RCUS (247M).
APLSRCUSAPLS / RCUS
Capitalization3.51B1.41B249%
EBITDA-298.3M-235M127%
Gain YTD-53.308-6.492821%
P/E RatioN/AN/A-
Revenue629M247M255%
Total Cash360M969M37%
Total Debt475M11M4,318%
FUNDAMENTALS RATINGS
APLS vs RCUS: Fundamental Ratings
APLS
RCUS
OUTLOOK RATING
1..100
558
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
9271
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
9148
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
4450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (56) in the Pharmaceuticals Major industry is in the same range as APLS (73) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

RCUS's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as APLS (92) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

RCUS's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as APLS (98) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

RCUS's Price Growth Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for APLS (91) in the Medical Distributors industry. This means that RCUS’s stock grew somewhat faster than APLS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as APLS (100) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSRCUS
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
78%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
N/A
IMVT - APLS
38%
Loosely correlated
+2.17%
PGEN - APLS
37%
Loosely correlated
+4.34%
ZYME - APLS
37%
Loosely correlated
-3.05%
FOLD - APLS
36%
Loosely correlated
+1.84%
INZY - APLS
35%
Loosely correlated
-1.12%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with NTLA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+0.45%
NTLA - RCUS
53%
Loosely correlated
+5.43%
PRME - RCUS
50%
Loosely correlated
+5.04%
DNLI - RCUS
50%
Loosely correlated
+3.02%
SNDX - RCUS
49%
Loosely correlated
+0.71%
PLRX - RCUS
49%
Loosely correlated
+8.00%
More